AbbVie to acquire clinical-stage firm Landos Biopharma for up to $212.5m
Through the deal, the American pharma major gains access to NX-13, Landos Biopharma’s flagship asset, which is being…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Mar 24
Through the deal, the American pharma major gains access to NX-13, Landos Biopharma’s flagship asset, which is being…
26 Mar 24
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
26 Mar 24
Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA)…
26 Mar 24
Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how Ultomiris may redefine patient journey for rare neurological…
26 Mar 24
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of…
26 Mar 24
XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital…
26 Mar 24
TNO spin-off Peregrion brings science to the marketplace
25 Mar 24
The FDA approval of Opsynvi, a combination of two proven treatments with established efficacy and safety profiles into…
25 Mar 24
The approval was based on the findings from the confirmatory Phase 3 MIRASOL trial in which Elahere treatment…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…